Chromosomal translocation t(11;14) and p53 deletion induced by the CRISPR/Cas9 system in normal B cell-derived iPS cells

Azami, Yusuke; Tsuyama, Naohiro; Abe, Yu; Sugai-Takahashi, Misaki; Kudo, Ken-ichi; Ota, Akinobu; Sivasundaram, Karnan; Muramatsu, Moe; Shigemura, Tomonari; Sasatani, Megumi; Hashimoto, Yuko; Saji, Shigehira; Kamiya, Kenji; Hanamura, Ichiro; Ikezoe, Takayuki; Onodera, Masafumi; Sakai, Akira

doi:10.1038/s41598-021-84628-5

Download PDF

Article
Open Access
Published: 04 March 2021

Chromosomal translocation t(11;14) and p53 deletion induced by the CRISPR/Cas9 system in normal B cell-derived iPS cells

Yusuke Azami¹,
Naohiro Tsuyama²,
Yu Abe²,
Misaki Sugai-Takahashi²,
Ken-ichi Kudo²,
Akinobu Ota³,
Karnan Sivasundaram³,
Moe Muramatsu⁴,
Tomonari Shigemura⁵,
Megumi Sasatani⁶,
Yuko Hashimoto⁴,
Shigehira Saji¹,
Kenji Kamiya⁶,
Ichiro Hanamura³,
Takayuki Ikezoe⁷,
Masafumi Onodera⁸ &
…
Akira Sakai²

Scientific Reports volume 11, Article number: 5216 (2021) Cite this article

2488 Accesses
2 Citations
2 Altmetric
Metrics details

Subjects

Abstract

Multiple myeloma (MM) cells are derived from mature B cells based on immunoglobulin heavy chain (IgH) gene analysis. The onset of MM is often caused by a reciprocal chromosomal translocation (cTr) between chr 14 with IgH and chr 11 with CCND1. We propose that mature B cells gain potential to transform by reprograming, and then chromosomal aberrations cause the development of abnormal B cells as a myeloma-initiating cell during B cell redifferentiation. To study myeloma-initiating cells, we have already established normal B cell-derived induced pluripotent stem cells (BiPSCs). Here we established two BiPSCs with reciprocal cTr t(11;14) using the CRISPR/Cas9 system; the cleavage site were located in the IgH Eμ region of either the VDJ rearranged allele or non-rearranged allele of IgH and the 5′-upsteam region of the CCND1 (two types of BiPSC13 with t(11;14) and MIB2-6 with t(11;14)). Furthermore, p53 was deleted using the CRISPR/Cas9 system in BiPSC13 with t(11;14). These BiPSCs differentiated into hematopoietic progenitor cells (HPCs). However, unlike cord blood, those HPCs did not differentiated into B lymphocytes by co-culture with BM stromal cell. Therefore, further ingenuity is required to differentiate those BiPSCs-derived HPCs into B lymphocytes.

Introduction

The cellular origin of multiple myeloma (MM) has not been identified. Based on the experiments of transplantation of bone marrow (BM) samples from MM patients into immunodeficient mice, so-called myeloma stem cells have been inferred to be present in CD19⁻/CD38⁺⁺/CD138⁺ or CD138⁻ plasma cell populations^1,2; however, the results may indicate the presence of plasma cell populations with cell proliferation ability rather than the cellular origin of myeloma cells. On the other hand, based on immunoglobulin heavy chain (IgH) gene analysis, myeloma cells are derived from post germinal centre B cells³ (Figure S1). Chromosomal aberrations such as trisomy and chromosomal translocation (cTr) play a critical role in early tumorigenesis of MM^4,5. We established induced pluripotent stem (iPS) cells from normal B lymphocytes (BiPSCs: BiPSC13 and MIB2-6) to test the hypothesis that the abnormal cells of origin responsible for tumorigenesis of MM are reprogrammed mature B lymphocytes⁶, and these BiPSCs have the same VDJ rearrangement of IgH as the original B lymphocytes and differentiate into CD34⁺/CD38⁻ hematopoietic progenitor cells (HPCs) when co-cultured with stromal cells. Furthermore, these cells can induce the expression of activation-induced cytidine deaminase (AID) that causes mutations not only in IgH but also in other genes, and further causes double strand breaks in DNA.

Here we generated BiPSCs with reciprocal cTr t(11;14), which is reciprocal translocation between IgH and CCND1 and the most frequent cTr in MM^4,5, using the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system⁷. Furthermore, we generated BiPSC13 with t(11;14) with a deletion in exon 5 of p53 because deletion of p53 is involved in the progression of MM^4,5 (Figure S2). Subsequently, we analyzed the features of cTr t(11;14) between the functional allele or the non-functional allele of IgH and CCND1 and the ability to differentiate into blood cells.

Results

Construction of IgH/cyclin D1-specific CRISPR/Cas9

The CCND1 cleavage site on chr 11 was upstream of CCND1 where off-target effects are fewer and setting a protospacer adjacent motif (PAM) site is easy, based on a study showing no hot spots at the cleavage site in the analysis of MM patients⁸. The IgH cleavage site on chr 14 was targeted at a site with fewer off-target effects, between Eμ and Iμ in the class switch region of IgH, and where setting a PAM site is easy⁹. We then designed a CRISPR/Cas9 vector in which these were arranged in tandem to obtain artificial induction of t(11;14) by cutting CCND1 upstream on chr 11 and between Eµ and Iµ regions of IgH on chr 14. We designed two efficient gRNA sequences to be expressed in one CRISPR/Cas9 vector⁷. The functioning of this system was confirmed by induction of cTr t(11;14) in 293 T cells⁷. We attempted to induce reciprocal cTr t(11;14) in two normal B lymphocyte-derived iPS cell lines (BiPSC13, MIB2-6) using the above method. In both BiPSC13 and MIB2-6, IgH has a complete VDJ rearrangement (VH3-FR1: V_3-9D_4-23J₂ in BiPSC13, VH4-FR1: V_4-39D_3-22J₆ in MIB2-6), no class switch recombination (CSR) of IgH (Supplemental information, Figure S3), and no somatic hypermutations (SHM) in the VDJ region compared to germline (Supplemental information, Figure S4A and S4C).

Two pairs of IgH on chr 14 and CCND1 on chr 11 of BiPSC13 and MIB2-6 are shown in Fig. 1A,D. In BiPSC13, the upper and lower alleles of chr 14 show the non-functional allele that stopped at DJ rearrangement (D_2-21J₂) and the functional allele that completed VDJ rearrangement (V_3-9D_4-23J₂) of IgH, respectively (Figure S4A and S4B). In MIB2-6, the upper and lower alleles of chr 14 show the non-functional allele in which DJ rearrangement was incomplete (D_5-18J₄), and the functional allele in which VDJ rearrangement was complte (V_4-39D_3-22J₆) for IgH, respectively (Figure S4C and S4D). The DJ joining of the non-functional allele of MIB2-6 was incomplete because DH4, DH6, and DH7 were deleted between D_5-18 and J₄, but an intron of 1000 bases or more remained (Figure S4D).

Using the CRISPR/Cas9 system, we induced two kinds of reciprocal cTr t(11, 14), in which the translocation allele of IgH was different, in BiPSC13 and MIB2-6 (BiPSC13 t(11;14) and MIB2-6 t(11;14), respectively). AZ and AX were the different types of BiPSC13 t(11;14) carrying either the VDJ-rearranged allele or the DJ-rearranged allele of IgH, respectively, that reciprocally translocated with CCND1 (Fig. 1B,C). BC and BG were the different types of MIB2-6 t(11;14) carrying either the VDJ-rearranged allele or the DJ-rearranged allele of IgH, respectively, that reciprocally translocated with CCND1 (Fig. 1E,F).

The features of these cTrs were confirmed with PCR using translocation-specific primers (Fig. 1). The PCR product in lane 1 shows the presence of the VDJ-rearranged functional allele of IgH, and the PCR product in lane 2 shows the non-functional allele that stopped at DJ rearrangement of IgH. Therefore, the PCR product in lane 3 shows the translocation between the functional allele of IgH and CCND1, and the PCR product in lane 4 shows the translocation between the non-functional allele of IgH and CCND1 (Fig. 1G,H). Among these cTrs, when the VDJ side of the IgH functional allele translocated with CCND1 upstream, der(11)t(11;14) was formed. Simultaneously, the CDS side of CCND1 translocated with the constant region of IgH, and der(14)t(11;14) was formed (AZ and BC) (Fig. 1B,E,G–I). On the other hand, when the DJ side of the non-functional allele of IgH translocated with CCND1 upstream, der(11)t(11;14) was formed. Simultaneously, the CDS side of CCND1 translocated with the constant region of IgH, and der(14)t(11;14) was formed (AX and BG) (Fig. 1C,F,G–I). Therefore, we established cell lines carrying reciprocal cTr t(11;14) between CCND1 and either an allele in which VDJ rearrangement of IgH was completed or an allele in which VDJ rearrangement was not completed (stopped at DJ joining) in BiPSC13 t(11;14)(AZ and AX)and MIB2-6 t(11;14) (BC and BG), respectively. We also confirmed the reciprocal cTr t(11;14) using IGH-CCND1 FISH (Fig. 1J,K).

Subsequently, we analyzed the nucleotide sequences near the translocation sites of AZ and AX, and BC and BG (Fig. 1L,M). Thirteen-base deletion of the CCND1 gRNA region and three-base deletion of the IgH gRNA region in der(11)t(11;14) of AX, and three-base addition at the translocation junction in der(14)t(11;14) of AX were confirmed (Fig. 1L). The cleavage site was 140 bases downstream from the PAM region of CCND1 gRNA in der(11)t(11;14) of BC, and 11-base deletion in the CCND1 gRNA region was confirmed (Fig. 1M). One-base deletion in the CCND1 gRNA and 30-base deletion in the Eμ direction from the IgH gRNA in der(11)t(11;14) of BG, and 2-base deletion in the IgH gRNA region in der(14)t(11;14) of BG were confirmed (Fig. 1M).

Effects of CRISPR/Cas9 on alleles of IgH not used in the translocation with CCND1 and on alleles of CCND1 not used in the translocation with IgH were also analyzed (Supplemental information, Figure S5 and S6). Deletions from 11 to 333 bases were found around the cleavage sites of Cas9 in those BiPSCs.

Knockout of TP53 with the CRISPR/Cas9 system

Because deletion of chr 17p, including p53 deletion, is involved in the progression of MM, genome editing was performed on p53 in BiPSC13 t(11;14) (AX) using the CRISPR/Cas9 system. The expression of TP53 was knocked out by deleting 83 bp of exon 5 of p53 (G#28: Fig. 2). Subsequently, we established G#28 and AX with AID expression regulated by the doxycycline-controlled (Tet-off) system (G#28-AID and AX-AID)⁶ (Supplemental information, Figure S7).

Differentiation of BiPSCs into blood cells

Initially, the induction of differentiation into HPC was performed by co-culturing BiPSC13, MIB2-6 with AGM-S3¹⁰ (Supplemenatal information, Figure S8). However, the differentiation efficiency was not stable, and AGM-S3 contamination was present even after purification using CD34 microbeads. We then used the STEMdiff Hematopoietic Kit to induce differentiation of BiPSCs into HPCs (Fig. 3). Based on a model of hematopoietic differentiation from human embryonic stem cells¹¹, the expression of CD43, CD45, and CD38 was examined in CD34⁺ cells. Except for AX (Fig. 3C), two cell populations were observed (R1 and R2), and most CD34⁺ cells were CD43⁺/CD45⁺/CD38^+/− in both populations (Fig. 3). The number of colonies formed in the colony assay is shown in Fig. 3I. Most colonies were a mix of macrophages and granulocytes, and some were mixed with erythrocytes (Fig. 3A–D,G,H). BC differentiated into CD34⁺ cells, but colony formation was not observed (Fig. 3F). On the other hand, differentiation into blood cells was observed even in the case of p53 deletion and induction of AID expression in the colony assay in AX (Fig. 3G,H). Therefore, B cell-derived iPS cells were able to differentiate into HPCs even in the presence of cTr t(11;14) or p53 was deletion.

Differentiation of BiPSCs-derived CD34⁺ cells and cord blood (CB) into B lymphocyte

We investigated whether HPCs differentiated from iPS cells derived from normal B lymphocytes can differentiate into B lymphocyte again by co-culture with MS-5, with reference to a study by MacLean¹². First, we confirmed that CB would differentiate into B lymphocytes by co-culture with MS-5, with reference to studies by Nishihara¹³ and Hirose¹⁴. CB proliferated rapidly after initiating the co-culture, and phenotype analysis at day 10 revealed that CD34⁺ cells were mainly present in the R2 region (Fig. 4A). The main cell population in both the R1 and R2 regions was CD34⁻/CD38^+/−/CD43⁺/CD45⁺, followed by CD34⁺/CD38⁻/CD43⁺/CD45⁺ (Fig. 4A). Four weeks after initiating the co-culture, the CD34⁺ cells had disappeared and the main cell populations were CD34⁻/CD38^+/−/CD43⁺/CD45⁺, and CD19⁺/CD10⁻ cells were observed in R2 region (Fig. 4B). The number of CD19⁺/CD10⁻ cells further increased 6 weeks after initiation of the co-culture (Fig. 4B).

Next, we investigated whether two types of BiPSCs (BiPSC13 and MIB2-6) would differentiate into B lymphocytes by co-culture with MS-5. The cells were differentiated into CD34⁺ cells using a STEMdiff Hematopoietic kit, and purified CD34⁺ cells were subsequently cultured on MS-5. Phenotype analysis was performed 3 weeks after initiation of the co-culture, with reference to a previous study¹². Based on studies reporting the appearance of CD19⁺ cells from the fourth week of co-culture of CB with MS-5^13,14, we performed phenotype analyses 4 or 5 weeks after initiation of the co-culture. Analysis of BiPSC13-derived cells showed a non-specific cell population, even after staining with an isotype control using FITC or without staining (Figure S9). Therefore, the cell population observed by the double staining of CD34/CD38 and CD19/CD10 was likely to be due to autofluorescence. In the co-culture of BiPSC13 or MIB2-6-derived CD34⁺ cells with MS-5, the CD34⁺ cells remained mainly in the R1 region and their phenotype were CD34⁺/CD38⁻/CD43⁻/CD45⁻ (Fig. 4C,D). A population of CD34⁻/CD38⁻/CD43⁺/CD45⁺ cells was also observed (Fig. 4C,D). No CD19⁺ cells were observed. In the co-culture of G#28-AID-derived CD34⁺ cells with MS-5, CD34⁺ cells were still found in both the R1 and R2 regions and their phenotype was CD34⁺/CD38⁻/CD43⁻/CD45⁻ (Fig. 4E).

Therefore, the critical difference between these three types of BiPSCs-derived HPCs and CB was that the former CD34⁺ cells remained and did not differentiate into CD38⁺ cells even after 4 weeks of co-culture with MS-5.

Discussion

We hypothesized that the abnormal cells from which myeloma cells originate may be mature B lymphocytes with chromosomal or genetic changes in the reprogrammed state that enable them to acquire the potential to become tumor cells during the process of redifferentiation into B lymphocytes. Here we tried to generate cells to test this hypothesis. First, we established iPS cells from normal B lymphocytes (BiPSCs) that can induce AID expression⁶. We then generated BiPSCs carrying the most frequent reciprocal cTr t(11;14) in MM (BiPSC13 t(11;14) and MIB2-6 t(11;14)), and also generated BiPSC13 t(11;14) with p53 deletion, which is involved in the progression of MM. This means “Strike (chromosomal or genetic changes) while the iron (B lymphocytes) is hot”.

Studies have reported the possibility of generating reprogrammed tumor cells or precancerous lesions by forcibly expressing the Yamanaka factors in colonic epithelium or pancreatic acinar cells that already have gene mutations^15,16. Interestingly, in vivo reprograming is possible in the presence of inflammation and senescence instead of Yamanaka factors, and depolarization of the original cell is considered to be critical¹⁷. We believe that normal B lymphocytes could be transformed into iPS-like cells in the environment of BM or lymph nodes in which Yamanaka factors are induced due to chronic inflammation. The original cells of BiPSCs were normal cells, unlike the cells mentioned above^15,16, and genomic changes were induced after transformation into iPS cells.

The onset of MM is often caused by a reciprocal cTr between chr 14 with IgH and chr 11 with CCND1 or chr 4 with FGFR3 and MMSET^4,5. In follicular lymphoma (FL) and mantle cell lymphoma (MCL), immature B lymphocytes in BM are considered the origin of tumor cells; the reciprocal cTr between IgH and oncogenes such as BCL-2 on chr 18 or CCND1 on chr 11 during VDJ rearrangement is responsible for tumorigenesis of B lymphocytes¹⁸. On the other hand, in MM, mature B lymphocytes, so-called plasma cells, or antibody-producing cells, are considered tumor cells because IgH reciprocally translocate with other genes during CSR^19,20, and SHM is recognized in the VDJ region of IgH^21,22,23. Considering the presence of M-protein, a functional allele of IgH is present in MM. Therefore, cTr occurs between another non-functional allele of IgH in which VDJ rearrangement has not been completed, and other chromosomes in MM³. The features of cTr in AX and BG exactly mimic that of MM.

When VDJ rearrangement of one allele of IgH is complete, VDJ rearrangement of another allele of IgH is not complete as a non-functional allele due to allelic exclusion^24,25. In FL and MCL, cTr occurs during VDJ rearrangement in immature B lymphocytes as mentioned above. However, considering that B-cell receptors are expressed on the cell surface, the allele that initiates VDJ rearrangement earlier would be a non-functional allele due to cTr, and in turn, another allele that should have been non-functional, would undergo VDJ rearrangement to create a functional allele that expresses B-cell receptors. Although cTr during VDJ rearrangement in MM was also reported²⁶, many cTrs occur during CSR^4,5.

Even in immature B lymphocytes, cTr t(14;18) or cTr t(11;14) alone is believed to not be able to transform these B lymphocytes, as suggested by studies revealing these chromosomal aberrations in normal individuals^27,28,29. Similarly, mature B lymphocytes would be unlikely to transform into tumor cells by cTr. Myeloma cells could be derived from reprogramed mature B lymphocytes with the following features: the CD19 antigen on the cell surface and its transcription factor, Pax5, are deleted in myeloma cells unlike in other B cell lymphomas³⁰. Furthermore, myeloma cells expressing CD33³¹, which is a cell surface marker of granulocytes, or producing amylase^32,33 or ammonia³⁴ have been reported.

Myeloma cells are derived from mature B lymphocytes because of SHM in the VDJ region of IgH (Figure S10). Because neither SHM in the VDJ region nor CSR of IgH occurred in BiPSC13 or MIB2-6, those BiPSCs are considered to be derived from pre-germinal center (GC) B lymphocytes rather than mature B lymphocytes. However, they can induce AID expression with the tet-off system⁶, and we confirmed that those BiPSCs and BiPSCs with t(11;14) can differentiate into HPCs in this study. If they further redifferentiate into B lymphocytes, SHM in the VDJ region and CSR of the functional allele of IgH could be induced during the redifferentiation process by activation of endogenous AID. Furthermore, activation of enhancers involved in IgH expression during the process of redifferentiation into B lymphocytes would lead to overexpression of CCND1 induced by cTr t(11;14), which is observed in MM with t(11;14). Expression of AID also would be expected to induce SHMs on various genes other than IgH, which would lead to the branching pathway theory based on a Darwinian selection perspective³⁵, a model for the progression of MM. In addition, if IgH expression is impossible due to a deletion in the constant region instead of CSR in the functional allele, this would be considered a mechanism of development of Bence-Jones-type MM; only the light chain of the M-protein is detected in the urine (and serum), because myeloma cells in these cases do not produce the IgH chain.

Unfortunately, no CD19⁺ cells were observed in co-culture of BiPSCs-derived CD34⁺ cells with MS-5. The difference between these BiPSCs-derived HPCs and CB was that the former CD34⁺ cells remained and CD34⁻/CD43⁺/CD45⁺ cells did not express CD38 even after 4 weeks of co-culture with MS-5. Especially, compared with the parent cell (BiPSC13), G#28-AID did not differentiate into CD34⁻/CD43⁺/CD45⁺ cells with remaining of CD34⁺ cells even 6 weeks after the initiation of co-culture with MS-5. A deletion of p53 might be involved in this feature. Given that CD38 is involved in lymphocyte activation^36,37, the ability to express CD38 in differentiation from HPC could be important for differentiation into B lymphocytes. Considering the results of the colony assay, a differentiation potential into blood cells of BiPSCs-derived HPCs can be expected, so other factors could be required for co-culture with MS5 in order to differentiate them into B lymphocytes in vitro. Moreover, important questions are whether these BiPSCs with cTr or p53 deletion are capable of forming MM or B lymphoid tumor cells, and whether AID induction induces additional genetic aberrations. We are planning to transplant these BiPSC-derived HPCs into BM of immunodeficienct mice.

Materials and methods

Materials

Plasmids used in this study, lentiCRISPRv2 (#98,290) were obtained from Addgene (www.addgene.org). lentiCRISPRv2 was a gift from Brett Stringer. Synthetic oligonucleotides and PCR primers were purchased from Eurofin Genomics (Tokyo, Japan). DNAiso was purchased from Takara bio (Kyoto, Japan). Thunderbird SYBR qPCR Mix and KOD-FX Neo were obtained from Toyobo (Tokyo, Japan). PEImax 40,000 was obtained from Polyscience Inc. (Warrington, PA, USA).

Normal B cell-derived iPS cell (BiPSCs: BiPSC13, MIB2-6) culture

Established BiPSCs were maintained in a six-well plate coated with iMatrix-511 (Nippi, Tokyo, Japan) in BiPSC culture medium, StemFit AK02N (REPROCELL, Yokohama, Japan). The BiPSC culture medium was changed every day until the start of differentiation experiment using the STEMdiff Hematopoietic Kit (STEMCELL Technologies, Vancouver, Canada).

Induction of translocation

cTr was induced by infection of BiPSCs with IgH-CCND1 lentiCRISPRv2 lentivirus which targets the human IgH Eµ region and 13 kb upstream of the CCND1 coding sequence (CDS)⁷. Briefly, CRISPRscan (http://www.crisprscan.org/)³⁸ estimated the gRNA candidate, 5′-GGAGAACATACCAAGCCCCAC-3′ for IgH (105,861,064 to 105,861,045 of NC_000014.9, chromosome (chr) 14, GRCh38.p12 Primary Assembly) and 5′-GGTGGCGAGGTGGGACCGCGG-3′ for CCND1 (69,627,757 to 69,627,776 of NC_000011, chr 11, GRCh38.p12 Primary Assembly), which were recombined into the lentiCRISPRv2 BsmBI site. The CCND1 gRNA expression unit of CCND1-lentiCRISPRv2 was cloned into IgH-lentiCRISPRv2 to form the IgH-CCND1 lentiCRISPRv2 dual site targeting vector. The vector was packaged into lentivirus, and BiPSCs cultures were infected with the packaged virus in the presence of polybrene (4 µg/mL) for 1 day. Puromycin selection (0.25 µg/mL) started after 2 days. Ten days later, drug-resistant colonies were picked and mechanically divided into two portions using pipet tips; one half was cultured, and DNA was isolated from the other half using DNAiso kit. Confirmation of cTr was performed by PCR using the IgH/CCND1 translocation-specific primer pair (IgH-Fs for the IgH side and CCND1-86-Rs for the CCND1 side) (Fig. 1, Table S1) with Thunderbird SYBR qPCR Mix and a Light Cycler Nano (Loche Diagnostics, Basel, Switzerland). PCR conditions were 94 °C 120 s, 50 cycles of (94 °C 10 s, 62 °C 10 s, 72 °C 20 s), and 72 °C to 94 °C at 0.1 °C/sec for melting temperature measurement. The presence of Tr-positive clones was assessed based on the melting temperature of PCR-amplified DNA compared with positive control DNA, which was the product amplified from the IgH and CCND1 genomic region with PCR and recombined into a translocation-mimic PCR template (5′-IgH-CCND1-3′)⁷.

Detection of VDJ and DJ rearrangements in BiPSCs

Confirmation of the VDJ recombination profile was performed as described³⁹. Briefly, VDJ regions from BiPSC genomic DNA were amplified with PCR using primer pairs of VHn-FR1 (n = 1–6) and JH consensus for the functional IgH allele, and DH regions were amplified using primer pairs of DHn (n = 1–7) and JH consensus for the non-functional IgH allele. Primers are listed in Table S1. PCR conditions are 95 °C 120 s, 45 cycles of (95 °C 30 s, 62 °C 15 s, 72 °C 40 s) using TB Green Fast qPCR Mix and LightCycler Nano. PCR products were electrophoresed in an agarose gel, and bands of the corresponding size were purified using FastGene Gel/PCR Extraction Kit (NIPPON Genetics) and sequenced with the same primers for PCR (FASMAC Co. Ltd.). Sequence data were analyzed using the IgBLAST database (https://www.ncbi.nlm.nih.gov/igblast/) to identify the subtype of every subdomain. An additional primer, DH5-18-F was used for DNA sequence of the non-functional IgH allele of MIB2-6.

Identification of reciprocal chromosomal translocation t(11;14)

VH3-FR1 primer for BiPSC13 or VH4-FR1 primer for MIB2-6 was used in combination with the CCND1-86-F primer to detect reciprocal cTr, which formed der(11)t(11;14), between the functional IgH allele and CCND1. DH2 primer for BiPSC13 or DH5 primer for MIB2-6 was used with the CCND1-86-F to detect reciprocal cTr, which formed der(11)t(11;14) between the non-functional IgH allele and CCND1. The combination of IgH-Fs and CCND1-86-R or CCND1-86-Rs was used to detect another reciprocal cTr forming der(14)t(11;14). The presence of the untranslocated allele of IgH was confirmed with PCR in the combinations of DH2 or VH3-FR1 and IgH-Fs for BiPSC13 and DH5 or VH4-FR1 and IgH-Fs for MIB2-6, respectively. The presence of the untranslocated allele of CCND1 was confirmed with PCR in the combination of CCND1-86-F and CCND1-86-R for both BiPSCs (Fig. 1A–F). Long PCR was performed using KOD FX Neo DNA polymerase and LifeTouch (BIOER Tech., Hangzhou, P. R. China). PCR conditions were 94 °C 120 s, 35 cycles of (94 °C 10 s, 64 °C 10 s, 68 °C 3 min). PCR products were electrophoresed in agarose gels, and gel images were obtained in a ChemDoc XRS + Imaging System and Image Lab 4.1 software (BIO-RAD, Hercules, CA, USA). Exposure time to obtain images was automatically adjusted to detect faint bands by the software. For DNA sequencing, major bands were purified using FastGene Gel/PCR Extraction Kit (Nippon Genetics, Tokyo, Japan). DNA sequences were analyzed by FASMAC (Atsugi, Japan) using primers for PCR positioned at translocation junction sites. Obtained sequences were aligned to IgH or CCND1 genome sequences to confirm sequence identity and alterations using ApE (http://jorgensen.biology.utah.edu/wayned/ape/) and NCBI Blast (https://blast.ncbi.nlm.nih.gov/). The existence of the non-translocated allele of IgH was also confirmed with PCR in the combination of VH3-FR1 primer for BiPSC13 or VH4-FR1 primer for MIB2-6 with IgH-Fs in the same condition of long PCR for the detection of cTr described above. All primers are listed in Table S1.

TP53 knockout using the CRISPR/Cas9 system

The CRISPR/Cas9 system was used to disrupt expression of TP53⁴⁰. The pSpCas9(BB)-2A-GFP (PX458) vector was a gift from Feng Zhang (Addgene plasmids # 48,138). In brief, a single guide RNA (sgRNA) sequence was selected using E-CRISP (http://www.e-crisp.org/E-CRISP/index.html). The sgRNA sequence for TP53 Exon 5 was 5′-GTTGATTCCACACCCCCGCC, which corresponds to the sequence on the 3′ side of the initiation codon of Δ133p53. The plasmid expressing hCas9 and TP53 sgRNA was prepared by ligating oligonucleotides into the BbsI site of PX458 (TP53ex5/PX458). To generate a TP53 knockout clone, 1 μg TP53ex5/PX458 plasmid was nucleofected into BiPSC13 with t(11;14) (AX) (1 × 10⁶ cells) using a 4D-Nucleofector instrument (Lonza Japan, Tokyo, Japan). After 3 days, cells expressing GFP were sorted using FACSAria (BD Bioscience, Franklin Lakes, NJ, USA), and single-cell cloning was performed. A single clone was selected, expanded, and used for biological assays. For sequence analysis of TP53 exon 5, the following primer set was used to amplify genomic DNA: 5′-TTGCAGGAGGTGCTTACACA and 5′-GAATTCTGAAGGTCTCGTCGT.

Culture of BiPSCs in stem cell differentiation medium for differentiation into HPCs

Differentiation of BiPSCs into HPC was performed using STEMdiff Hematopoietic Kit (STEMCELL Technologies, Vancouver, Canada). BiPSCs were cultured on Matrigel hESC-Qualified Matrix (CORNING, Corning, NY, USA), incubated with Gentle Cell Dissociation Reagent (STEMCELL Technologies) at room temperature for 4–6 min, removed using a scraper, and then, 50 μm-sized pieces were transferred to a matrigel-coated 12-well plate in Complete StemFit AK02N (100 pieces/well). Differentiation experiments were performed according to the instructions of the kit. BiPSCs with AID were cultured in the presence of 10 ng/mL doxycycline (Takara Bio, Kusatsu, Japan) to prevent AID expression. Concurrently, CD34⁺ cells were purified using MACS CD34 MicroBeads (Miltenyi Biotec Inc., Auburn, CA, USA) according to the manufacturer’s instructions, and the collected cells were used for phenotype analysis and a colony-forming assay.

Phenotype analysis

Purified CD34⁺ cells were evaluated by two-color and three-color flow cytometry after staining in phosphate-buffered saline without calcium chloride or magnesium chloride with the following monoclonal antibodies: anti-CD19-PE, anti-CD34-PE (BioLegend, San Diego, CA, USA), anti-CD38-FITC, anti-CD43-FITC, anti-CD10-FITC (BioLegend), and anti-CD45-PE/Cy5 (BioLegend). Immunofluorescence of the labeled cell membrane was evaluated using a flow cytometer (S3e Cell Sorter; BIO-RAD). Furthermore, phenotype analysis was performed after co-culture of CD34⁺ cells with MS-5⁴¹.

Colony-forming assay

Purified CD34⁺ cells were then used in colony-forming assays using Methocult H4435 (STEMCELL Technologies) in triplicate. The types of colonies formed were assessed around day 14.

cTr t(11;14)-specific fluorescence in situ hybridization (FISH)

cTr t(11;14)-specific FISH was performed by LSI Medience (LSI Medience Corporation, Tokyo, Japan).

Western blot analysis

The method was described in our previous study⁶. Briefly, cells were lysed in lysis buffer (0.5% NP-40, 1% TritonX-100, 150 mM NaCl, and 1 mM EDTA in 20 mM Tris, pH 7.5) with a protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan) and PhosSTOP phosphatase inhibitor cocktail (Roche Diagnosis). After ten min on ice, the cell lysates were centrifuged at 14,000 rpm for 10 min at 4 °C and the supernatants were recovered. Protein content of every sample was measured by Bradford method, and protein of 70 µg aliquots were separated in a Mini-PROTEAN TGX precast Gel (BIO-RAD) and transferred to a nitrocellulose membrane (BIO-RAD). The membrane was incubated with the indicated antibodies and horseradish peroxidase (HRP)-labeled secondary antibodies, and the signal was visualized with enhanced Chemi-Lumi One Super (Nacalai Tesque) and detected by the ChemDoc XRS + (BIO-RAD). The primary antibodies used were anti-AICDA (Abcam Japan, Tokyo, Japan), p53 (DO-1) (Santa Cruz Biotech, Dallas, TX, USA), and anti-GAPDH (Abcam) and the second antibody was goat anti-mouse IgG-HRP or goat anti-rabbit IgG-HRP (Santa Cruz Biotech).

Co-culture of purified CD34⁺ cells or cord blood (CB) with MS-5 for differentiation into B lymphocyte

The murine BM stromal cell line MS-5⁴¹ (a kind gift from Dr. Katsuhiko Itoh, Kyoto University), was maintained in α-MEM (Nacalai Tesque) supplemented with 20% horse serum (HS) (JRH (SAFC) Biosciences, Inc. Lenexa, KS, USA) and 1% penicillin/streptomycin (PS) (Nacalai Tesque). The cells were cultured to approximately 80% confluency in a FALCON tissue culture flask 50 mL (CORNING) for co-culture with purified CD34⁺ cells differentiated from BiPSC13, MIB2-6 and G#28-AID, or in a six-well tissue plate (Becton Dickinson, Franklin Lakes, NJ, USA) for co-culture with human CD34⁺ progenitor cells from cord blood (CB) (hCD34⁺-CB, single donor; Takara Bio). CD34⁺ cells (1 × 10⁴ cells/mL) derived from BiPSC13, MIB2-6 and G#28-AID, and 0.5 × 10⁴ cells/mL of CD34⁺ cells from CB, were plated onto the MS-5 feeder cells in α-MEM supplemented with 10% FBS, 1% GlutaMAX (Thermo Fisher Scientific KK, Tokyo, Japan), 1-thioglycerol (4 × 10^–4 M, Sigma-Aldrich Japan, Tokyo, Japan), SCF (50 ng/mL) (BioLegend), G-CSF (25 ng/mL) (BioLegend), Flt3-L (50 ng/mL) (BioLegend), and IL-7 (20 ng/mL) (BioLegend). All cultures were performed in a humidified incubator containing 5% CO2 in air at 37 °C. Every 7 days, the cells were fed by removing half of the medium and replacing it with fresh medium containing fresh cytokines. Samples of CB co-cultured with MS-5 were collected after 10 days, 4 weeks and 6 weeks of co-culture, and the other samples were collected after 3–5 weeks of co-culture. For phenotype analysis, co-culture supernatant was collected, the MS-5 layer was incubated with collagenase IV (1 mg/mL) for 20 min at 37 °C, then the supernatant and MS-5 were combined and subjected to phenotype analysis.

References

Hosen, N. et al. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia 26, 2135–2141 (2012).
Article CAS PubMed Google Scholar
Kim, D., Park, C. Y., Medeiros, B. C. & Weissman, I. L. CD19- CD45low/- CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia 26, 2530–2537 (2012).
Article CAS PubMed Google Scholar
González, D. et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110, 3112–3121 (2007).
Article PubMed CAS Google Scholar
Morgan, G. J., Walker, B. A. & Davies, F. E. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 12, 335–348 (2012).
Article CAS PubMed Google Scholar
Kumar, S. K. et al. Multiple myeloma . Nat. Rev. Dis. Prim. 3, 1–20 (2017).
Google Scholar
Kawamura, F. et al. Establishment of induced pluripotent stem cells from normal B cells and inducing AID expression in their differentiation into hematopoietic progenitor cells. Sci. Rep. 7, 1–11 (2017).
Article CAS Google Scholar
Tsuyama, N. et al. Induction of t(11;14) igh enhancer/promoter-cyclin d1 gene translocation using crispr/cas9. Oncol. Lett. 18, 275–282 (2019).
CAS PubMed PubMed Central Google Scholar
Ronchetti, D. et al. Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood 93, 1330–1337 (1999).
Article CAS PubMed Google Scholar
Fenton, J. A. L., Pratt, G., Rothwell, D. G., Rawstron, A. C. & Morgan, G. J. Translocation t(11;14) in multiple myeloma: analysis of translocation breakpoints on der(11) and der(14) chromosomes suggests complex molecular mechanisms of recombination. Genes chromosom. . Cancer 39, 151–155 (2004).
CAS Google Scholar
Xu, M. J. et al. Stimulation of mouse and human primitive hematopoiesis by murine embryonic aorta-gonad-mesonephros-derived stromal cell lines. Blood 92, 2032–2040 (1998).
Article CAS PubMed Google Scholar
Vodyanik, M. A., Thomson, J. A. & Slukvin, I. I. Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures. Blood 108, 2095–2105 (2006).
Article CAS PubMed PubMed Central Google Scholar
MacLean, G. A. et al. Downregulation of endothelin receptor B contributes to defective B cell lymphopoiesis in trisomy 21 pluripotent stem cells. Sci. Rep. 8, 1–10 (2018).
Article CAS Google Scholar
Nishihara, M. et al. A combination of stem cell factor and granulocyte colony-stimulating factor enhances the growth of human progenitor B cells supported by murine stromal cell line MS-5. Eur. J. Immunol. 28, 855–864 (1998).
Article CAS PubMed Google Scholar
Hirose, Y. et al. B-cell precursors differentiated from cord blood CD34+ cells are more immature than those derived from granulocyte colony-stimulating factor-mobilized peripheral blood CD34+ cells. Immunology 104, 410–417 (2001).
Article CAS PubMed PubMed Central Google Scholar
Hashimoto, K. et al. Cellular context-dependent consequences of Apc mutations on gene regulation and cellular behavior. Proc. Natl. Acad. Sci. USA 114, 758–763 (2017).
Article CAS PubMed PubMed Central Google Scholar
Shibata, H. et al. In vivo reprogramming drives Kras-induced cancer development. Nat. Commun. 9, 1–7 (2018).
Article CAS Google Scholar
Taguchi, J. & Yamada, Y. Unveiling the role of senescence-induced cellular plasticity. Cell Stem Cell 20, 293–294 (2017).
Article CAS PubMed Google Scholar
Lieber, M. R. Mechanisms of human lymphoid chromosomal translocations. Nat. Rev. Cancer 16, 387–398 (2016).
Article CAS PubMed PubMed Central Google Scholar
Bergsagel, P. L. et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106, 296–303 (2005).
Article CAS PubMed PubMed Central Google Scholar
Chesi, M. et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13, 167–180 (2008).
Article CAS PubMed PubMed Central Google Scholar
Vescio, R. A. et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J. Immunol. 155, 2487–2497 (1995).
Article CAS PubMed Google Scholar
Sahota, B. S. S. et al. Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells. Blood 89, 219–226 (1997).
Article CAS PubMed Google Scholar
Kosmas, C. et al. Origin and diversification of the clonogenic cell in multiple myeloma: lessons from the immunoglobulin repertoire. Leukemia 14, 1718–1726 (2000).
Article CAS PubMed Google Scholar
Chang, Y., Bosma, M. J. & Bosma, G. C. Extended duration of DH-JH rearrangement in immunoglobulin heavy chain transgenic mice: Implications for regulation of allelic exclusion. J. Exp. Med. 189, 1295–1305 (1999).
Article CAS PubMed PubMed Central Google Scholar
Jung, D., Giallourakis, C., Mostoslavsky, R. & Alt, F. W. (2006) Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu. Rev. Immunol. 1, 541–570 (2006).
Article CAS Google Scholar
Morgan, G. et al. Characterization of IgH breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pre-germinal center B cells. Blood 121, 3413–3420 (2013).
Article PubMed Google Scholar
Yasukawa, M. et al. Low frequency of BCL-2/JH translocation in peripheral blood lymphocytes of healthy Japanese individuals. Blood 98, 486–488 (2001).
Article CAS PubMed Google Scholar
Roulland, S. et al. Follicular lymphoma-like B cells in healthy individuals: A novel intermediate step in early lymphomagenesis. J. Exp. Med. 203, 2425–2431 (2006).
Article CAS PubMed PubMed Central Google Scholar
Lecluse, Y. et al. T(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals. Leukemia 23, 1190–1193 (2009).
Article CAS PubMed Google Scholar
Mahmoud, M. S. et al. Altered expression of Pax-5 gene in human myeloma cells. Blood 87, 4311–4315 (1996).
Article CAS PubMed Google Scholar
Matsuo, Y. et al. Establishment and characterization of new IgD lambda type myeloma cell lines, MOLP-2 and MOLP-3, expressing CD28, CD33 antigens and the IL-6 receptor. Hum. Cell 6, 310–313 (1993).
CAS PubMed Google Scholar
Matsuzaki, H., Hata, H., Takeya, M. & Takatsuki, K. Establishment and characterization of an amylase-producing human myeloma cell line. Blood 72, 978–982 (1988).
Article CAS PubMed Google Scholar
Ohtsuki, T. et al. Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br. J. Haematol. 73, 199–204 (1989).
Article CAS PubMed Google Scholar
Matsuzaki, H. et al. Human Myeloma Cell Line (KHM-4) Established from a Patient with Multiple Myeloma Associated with Hyperammonemia. Intern. Med. 31, 339–343 (1992).
Article CAS PubMed Google Scholar
Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356–361 (2011).
Article ADS CAS PubMed Google Scholar
Schneider, M. et al. CD38 is expressed on inflammatory cells of the intestine and promotes intestinal inflammation. PLoS ONE 10, 1–16 (2015).
Article Google Scholar
Glaría, E. & Valledor, A. F. Roles of CD38 in the Immune Response to Infection. Cells 9, 228 (2020).
Article PubMed Central CAS Google Scholar
Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184–191 (2016).
Article CAS PubMed PubMed Central Google Scholar
van Dongen, J. J. M. et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 17, 2257–2317 (2003).
Article PubMed Google Scholar
Ota, A. et al. Δ40P53Α Suppresses Tumor Cell Proliferation and Induces Cellular Senescence in Hepatocellular Carcinoma Cells. J. Cell Sci. 130, 614–625 (2017).
CAS PubMed PubMed Central Google Scholar
Itoh, K. et al. A novel hematopoietic multilineage clone, Myl-D-7, is stromal cell-dependent and supported by an alternative mechanism(s) independent of stem cell factor/c-kit interaction. Blood 87, 3218–3228 (1996).
Article CAS PubMed Google Scholar

Download references

Acknowledgement

This work was supported in part by a Grant-in-Aid for Scientific Research (C), No. 20K08738 and by a Grant-in-Aid for Young Scientists, No. 20K16795, from the Japanese Ministry of Education, Culture, Sports, Science, and Technology, The Japanese Society of Hematology Research Grant, Japan Leukemia Research Fund, and Network-type Joint Usage/Research Center for Radiation Disaster Medical Science.

Author information

Authors and Affiliations

Department of Medical Oncology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan
Yusuke Azami & Shigehira Saji
Department of Radiation Life Sciences, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan
Naohiro Tsuyama, Yu Abe, Misaki Sugai-Takahashi, Ken-ichi Kudo & Akira Sakai
Department of Hematology, Aichi Medical University School of Medicine, Nagakute, 480-1195, Japan
Akinobu Ota, Karnan Sivasundaram & Ichiro Hanamura
Department of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan
Moe Muramatsu & Yuko Hashimoto
Department of Pediatrics, Shinshu University, Matsumoto, 390-8621, Japan
Tomonari Shigemura
Department of Experimental Oncology, RIRBM, Hiroshima University, Hiroshima, 734-8553, Japan
Megumi Sasatani & Kenji Kamiya
Department of Hematology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan
Takayuki Ikezoe
Department of Genetics, National Research Institute for Child Health, Development, Tokyo, 157-8535, Japan
Masafumi Onodera

Authors

Yusuke Azami
View author publications
You can also search for this author in PubMed Google Scholar
Naohiro Tsuyama
View author publications
You can also search for this author in PubMed Google Scholar
Yu Abe
View author publications
You can also search for this author in PubMed Google Scholar
Misaki Sugai-Takahashi
View author publications
You can also search for this author in PubMed Google Scholar
Ken-ichi Kudo
View author publications
You can also search for this author in PubMed Google Scholar
Akinobu Ota
View author publications
You can also search for this author in PubMed Google Scholar
Karnan Sivasundaram
View author publications
You can also search for this author in PubMed Google Scholar
Moe Muramatsu
View author publications
You can also search for this author in PubMed Google Scholar
Tomonari Shigemura
View author publications
You can also search for this author in PubMed Google Scholar
Megumi Sasatani
View author publications
You can also search for this author in PubMed Google Scholar
Yuko Hashimoto
View author publications
You can also search for this author in PubMed Google Scholar
Shigehira Saji
View author publications
You can also search for this author in PubMed Google Scholar
Kenji Kamiya
View author publications
You can also search for this author in PubMed Google Scholar
Ichiro Hanamura
View author publications
You can also search for this author in PubMed Google Scholar
Takayuki Ikezoe
View author publications
You can also search for this author in PubMed Google Scholar
Masafumi Onodera
View author publications
You can also search for this author in PubMed Google Scholar
Akira Sakai
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization, A.S.; Investigation, Y.A., N.T., Y.A., M.S., K.K., A.O., K.S., M.M., and A.S.; Validation, N.T. and A.S.; Methodology, T.S., M.S., S.S., K.K., I.H., T.I., M.O., Y.H. Writing-Original Draft, Y.A. and A.S. Writing-Review and Editing, N.T. and A.S. Funding Acquisition, Y.A. and A.S.; Project Administration, A.S.

Corresponding author

Correspondence to Akira Sakai.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Cite this article

Azami, Y., Tsuyama, N., Abe, Y. et al. Chromosomal translocation t(11;14) and p53 deletion induced by the CRISPR/Cas9 system in normal B cell-derived iPS cells. Sci Rep 11, 5216 (2021). https://doi.org/10.1038/s41598-021-84628-5

Download citation

Received: 03 November 2020
Accepted: 18 February 2021
Published: 04 March 2021
DOI: https://doi.org/10.1038/s41598-021-84628-5

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.